H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Beam Therapeutics today and set a price target of $80.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Patrick Trucchio has given his Buy rating due to a combination of factors tied to Beam’s advancing pipeline and strengthened balance sheet. He highlights the launch of BEAM-304 for phenylketonuria as a pivotal step into an “interventional genetics” model, alongside upcoming data from BEAM-302 in alpha-1 antitrypsin deficiency and a planned BLA submission for risto-cel in sickle cell disease by the end of 2026.
He also emphasizes the $500 million non-dilutive financing facility from Sixth Street and Beam’s $1.25 billion cash position, which together extend the company’s runway into mid-2029 and support the transition toward potential commercialization. In addition, Pfizer’s decision to license a liver-targeted candidate using Beam’s LNP technology serves as external validation of the platform, reinforcing his view that multiple clinical and regulatory catalysts over the next 12–18 months can unlock meaningful value, supporting an $80 price target and a Buy recommendation.
According to TipRanks, Trucchio is a 5-star analyst with an average return of 26.5% and a 50.20% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as COMPASS Pathways, Atai Beckley N.V., and Alnylam Pharma.
In another report released on February 25, Canaccord Genuity also maintained a Buy rating on the stock with a $75.00 price target.